Cargando…
Immunomodulation by α(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human α(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes
INTRODUCTION: Recombinant α(1)-proteinase inhibitor, clinically developed for inhalative augmentation therapy in patients with α(1)-proteinase inhibitor deficiency or cystic fibrosis, may directly contribute to leukocyte accumulation as it may function as a chemoattractant. The migratory effects of...
Autores principales: | Mosheimer, Birgit, Alzner, Reinhard, Wiedermann, Christian J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Birkhäuser-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766450/ https://www.ncbi.nlm.nih.gov/pubmed/18060368 http://dx.doi.org/10.1007/s00005-007-0045-3 |
Ejemplares similares
-
Expression of human α(1)-proteinase inhibitor in Aspergillus niger
por: Karnaukhova, Elena, et al.
Publicado: (2007) -
Lipopolysaccharide modulates the expression of alpha 1 proteinase inhibitor and other serine proteinase inhibitors in human monocytes and macrophages
Publicado: (1987) -
PROTEINASE INHIBITORS | Cystatins
por: Pemberton, P.A.
Publicado: (2006) -
Arterivirus Papain-like Proteinase 1α
por: Nedialkova, Danny D., et al.
Publicado: (2013) -
Proteolysis and Deficiency of α1-Proteinase Inhibitor in SARS-CoV-2 Infection
por: Akbasheva, O. E., et al.
Publicado: (2022)